[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE200100342A - Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks - Google Patents

Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks

Info

Publication number
EE200100342A
EE200100342A EEP200100342A EEP200100342A EE200100342A EE 200100342 A EE200100342 A EE 200100342A EE P200100342 A EEP200100342 A EE P200100342A EE P200100342 A EEP200100342 A EE P200100342A EE 200100342 A EE200100342 A EE 200100342A
Authority
EE
Estonia
Prior art keywords
less
pores
formulation
amount
case
Prior art date
Application number
EEP200100342A
Other languages
English (en)
Estonian (et)
Inventor
Cevc Gregor
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8167168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100342(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idea Ag filed Critical Idea Ag
Publication of EE200100342A publication Critical patent/EE200100342A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200100342A 1998-12-23 1998-12-23 Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks EE200100342A (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/008421 WO2000038653A1 (fr) 1998-12-23 1998-12-23 Formulation amelioree pour l'application topique non invasive in vivo

Publications (1)

Publication Number Publication Date
EE200100342A true EE200100342A (xx) 2002-10-15

Family

ID=8167168

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100342A EE200100342A (xx) 1998-12-23 1998-12-23 Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks

Country Status (22)

Country Link
US (2) US7175850B2 (fr)
EP (1) EP1140021B1 (fr)
JP (1) JP2002533379A (fr)
KR (1) KR100638150B1 (fr)
CN (1) CN1320880C (fr)
AT (1) ATE272391T1 (fr)
AU (1) AU770803B2 (fr)
BR (1) BR9816113A (fr)
CA (1) CA2356080C (fr)
CZ (1) CZ20012038A3 (fr)
DE (1) DE69825495T2 (fr)
EE (1) EE200100342A (fr)
ES (1) ES2226203T3 (fr)
HK (1) HK1040629B (fr)
HR (1) HRP20010309B1 (fr)
HU (1) HUP0104424A3 (fr)
MX (1) MXPA01006424A (fr)
NO (1) NO20013164L (fr)
PL (1) PL193824B1 (fr)
RU (1) RU2207844C2 (fr)
TR (1) TR200101790T2 (fr)
WO (1) WO2000038653A1 (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
HUP0102741A3 (en) * 1998-10-23 2002-12-28 Idea Ag Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
EP1140021B1 (fr) * 1998-12-23 2004-08-04 Idea Ag Formulation amelioree pour l'application topique non invasive in vivo
EP1031346B1 (fr) 1999-01-27 2002-05-02 Idea Ag Vaccination non invasive à travers la peau
DE69901284T2 (de) 1999-01-27 2002-11-28 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
AU2001277891A1 (en) * 2000-07-26 2002-02-05 Alcon Universal Ltd. Pharmaceutical suspension compositions lacking a polymeric suspending agent
CA2430897C (fr) 2000-12-07 2010-11-16 Universiteit Utrecht Holding B.V. Composition pour le traitement de maladies inflammatoires
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
AU2003233396B2 (en) * 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
US8367098B2 (en) 2002-04-30 2013-02-05 The Population Council, Inc. Unique combinations of antimicrobial compositions
EP1371362A1 (fr) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition pour le traitement de troubles inflammatoires
CN1671400A (zh) * 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
KR20050055723A (ko) * 2002-10-11 2005-06-13 이데아 아게 생체 내, 특히 피부를 통한 비침투성 약물 적용 및 반투성배리어를 통한 향상된 전달을 위한, 적어도 세 가지 양친성성분을 포함하는, 증가된 변형성을 갖는 응집체
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004054608A2 (fr) 2002-12-12 2004-07-01 Agennix Incorporated La lactoferrine en tant qu'analgesique
WO2004103285A2 (fr) * 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrine pour traitement du diabete sucre
NZ546073A (en) * 2003-09-22 2009-07-31 Innovation Technologies Inc Wound irrigation device and method
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
MXPA06009897A (es) 2004-03-03 2008-02-07 Revance Therapeutics Inc Composiciones y metodos para el diagnostico topico y el transporte terapeutico.
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
PL1755616T3 (pl) * 2004-04-08 2014-10-31 Eye Co Pty Ltd Leczenie mineralokortykoidami retinopatii wysiękowej
KR100772327B1 (ko) * 2004-04-22 2007-10-31 주식회사유한양행 하이드로코티손 또는 그 염을 함유하는 나노에멀젼 조성물
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
JP2008514606A (ja) * 2004-09-24 2008-05-08 リポ ケミカルズ インコーポレイテッド 局所適用化合物のためのデリバリーシステム
WO2006047744A2 (fr) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions de peptides en rapport avec la lactoferrine et utilisations
CA2584475A1 (fr) * 2004-11-12 2006-05-18 Idea Ag Agregats a grande surface pour le traitement de troubles cutanes
KR20070097092A (ko) * 2005-01-14 2007-10-02 리포 케미컬즈 인크. 과다색소침착된 피부 치료용 조성물 및 치료방법
MX2007010673A (es) 2005-03-03 2008-04-07 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
EP1888033B1 (fr) 2005-06-09 2014-02-19 Meda AB Methode et composition de traitement de troubles inflammatoires
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
HUE048521T2 (hu) 2005-08-31 2020-08-28 Abraxis Bioscience Llc Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
PT1919450E (pt) * 2005-09-01 2014-09-10 Meda Ab Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7998717B2 (en) * 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
WO2007102090A2 (fr) * 2006-03-06 2007-09-13 Fqubed Inc. Formulation topique
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US9642912B2 (en) 2006-03-06 2017-05-09 Crescita Therapeutics Inc. Topical formulations for treating skin conditions
US8343962B2 (en) * 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
ES2495965T3 (es) * 2006-08-16 2014-09-17 Action Medicines, S.L. Uso de derivados 2,5-dihidroxibencénicos para el tratamiento de enfermedades oculares
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
CN107080703A (zh) 2006-12-01 2017-08-22 安特里奥公司 肽纳米粒子和其用途
LT2094331T (lt) * 2006-12-19 2016-12-27 Innovation Technologies, Inc. Įtaisai ir sprendimai veikliosioms medžiagoms pristatyti į paskirties vietą
US20110097372A1 (en) * 2009-10-26 2011-04-28 Rucinski Paul J Devices, methods, and compositions for controlling infections
CN101032473B (zh) * 2007-04-05 2010-04-07 上海交通大学 三明治型药物缓释膜及其制备方法
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
ES2805225T3 (es) 2007-07-26 2021-02-11 Revance Therapeutics Inc Péptidos antimicrobianos y composiciones de los mismos
ITRM20070510A1 (it) * 2007-10-02 2009-04-03 Rmfa Trading S A Composizioni oftalmiche a base di polisaccaride del seme di tamarindo e acido ialuronico.
JP5643111B2 (ja) * 2008-01-18 2014-12-17 ホーファグ リサーチ アイピー （エムアイアール） リミテッド 異常な眼圧の治療
EP2444092B1 (fr) 2008-05-28 2015-09-02 ReveraGen BioPharma, Inc. Modulateurs stéroïdiens non hormonaux de nf-kb pour le traitement d une maladie
US8173147B2 (en) * 2008-08-15 2012-05-08 Xttrium Laboratories, Inc. Gentle, non-irritating, non-alcoholic skin disinfectant
US9220701B2 (en) * 2008-10-03 2015-12-29 Nexmed Holdings, Inc. Stabilized composition for treating psoriasis
PT2437726T (pt) * 2009-06-03 2018-08-10 Sequessome Tech Holdings Limited Formulações para o tratamento da dor de tecidos profundos
CN102770162B (zh) 2009-08-21 2016-09-28 靶向递送技术有限公司 囊泡制剂
EP2556083A4 (fr) 2010-04-05 2013-12-04 Validus Biopharma Inc Modulateurs stéroïdes non hormonaux de nf- kappa b pour le traitement de maladies
WO2012021733A2 (fr) 2010-08-12 2012-02-16 Pacific Biosciences Of California, Inc. Systèmes et composés pour atténuer une photodégradation
EP2637711B1 (fr) * 2010-11-10 2024-03-27 ProKidney Formulations injectables pour la régénération d'organe
US8236288B2 (en) 2011-01-07 2012-08-07 Skinmedica, Inc. Melanin modification compositions and methods of use
RU2456979C1 (ru) * 2011-04-11 2012-07-27 Общество с ограниченной ответственностью "ЭкоБиоФармДубна" Индометацин на основе фосфолипидных наночастиц для применения в офтальмологии
EP2726071B1 (fr) * 2011-06-29 2023-10-11 Avidas Pharmaceuticals LLC Formulations topiques comprenant des véhicules d'administration de microcapsules lipidiques et leurs utilisations
CN102847151B (zh) * 2011-07-01 2014-08-13 天津金耀集团有限公司 含有巯乙基磺酸钠和糖皮质激素的吸入制剂及其制备方法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
RU2477632C1 (ru) * 2011-12-22 2013-03-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Российский химико-технологический университет им. Д.И. Менделеева (РХТУ им. Д.И. Менделеева) Способ получения липосомальной формы биологически активного вещества
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
CN102772396B (zh) * 2012-07-25 2013-12-18 杭州普瑞美克生物科技有限公司 用于动物抓咬伤后皮肤清洁抗菌且配合使用的组合型制剂
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
GB2533235B (en) * 2013-07-31 2018-11-21 Sequessome Tech Holdings Limited Vesicles
US9309205B2 (en) 2013-10-28 2016-04-12 Wincom, Inc. Filtration process for purifying liquid azole heteroaromatic compound-containing mixtures
EP3116986B1 (fr) 2014-03-14 2023-07-05 GOJO Industries, Inc. Désinfectants pour les mains à caractéristiques améliorées de l'esthétique et de soins de la peau pour encourager le respect des instructions d'hygiène des mains
CA2947767A1 (fr) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Formulations d'hormones substitutives combinees naturelles et traitement hormonal substitutif
WO2016054079A1 (fr) 2014-09-29 2016-04-07 Zyomed Corp. Systèmes et procédés pour la détection et la mesure du glucose sanguin du sang et d'autres analytes à l'aide du calcul de collision
CA2974196C (fr) 2015-01-20 2023-12-12 TetraDerm Group LLC Vehicule d'administration de medicament topique polyvalent et hydratant tissulaire multifactoriel qui permet la restauration de la barriere muqueuse et cutanee
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
DK3316856T3 (da) 2015-06-30 2021-06-28 Sequessome Tech Holdings Limited Blandede formuleringer
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2016311235B2 (en) * 2015-08-24 2021-02-11 Smith & Nephew, Inc. Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms
CN107477368A (zh) * 2015-09-11 2017-12-15 刘玉友 一种用于提高原油减阻剂抗剪切性能的添加剂
WO2017146602A1 (fr) * 2016-02-24 2017-08-31 Arcasiu Nicolae Sels de chlore ou de brome de cétylpyridinium pour utilisation dans le traitement de porphyries cutanées et aiguës et du psoriasis
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10265280B2 (en) 2016-11-14 2019-04-23 Mingwu Wang Formulations for the treatment of ocular surface diseases and related methods
EP3541358A1 (fr) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Administration transdermique de grands agents
CN107970257A (zh) * 2017-12-22 2018-05-01 成都博创必成医药技术有限公司 一种耳用药物组合物、制备方法及其应用与耳用药物制剂
CN112533478A (zh) * 2018-08-08 2021-03-19 3M创新有限公司 治疗组合物和相关方法
DE102018133374A1 (de) * 2018-12-21 2020-06-25 Gelita Ag Kollagenhydrolysat zur Verwendung gegen Hautkrankheiten und Darmkrankheiten
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
CN111904932B (zh) * 2019-05-08 2023-06-20 北京德立福瑞医药科技有限公司 一种含有糖皮质激素的胶束制剂及其制备方法
CA3142247A1 (fr) 2019-07-01 2021-01-07 Oculis SA Procede de stabilisation du ph d'une composition aqueuse comprenant un medicament
DE102019218241A1 (de) * 2019-11-26 2021-05-27 Beiersdorf Ag Wirkstoffkombinationen aus Ubichinol und Carrageenan und kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN114831939B (zh) * 2021-01-30 2024-06-07 南京星银药业集团有限公司 一种醋酸曲安奈德组合物喷雾剂及其制备方法
CN113425845B (zh) * 2021-08-10 2022-12-02 成都倍特药业股份有限公司 一种预防和/或治疗脱发症的传递体制剂及其制备方法和用途
PL244294B1 (pl) * 2022-09-20 2024-01-03 Univ Medyczny W Lodzi Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153713A (en) 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
CA1134276A (fr) 1980-03-26 1982-10-26 Alec D. Keith Complexe d'alcanolamine et de phosphatide inferieur pour applications locales
JPS56135416A (en) 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
USRE33273E (en) 1982-08-18 1990-07-24 Georgia Tech Research Corporation Materials having improved nonfouling characteristics and method of making same
EP0152379A3 (fr) 1984-02-15 1986-10-29 Ciba-Geigy Ag Procédé pour la préparation de compositions pharmaceutiques contenant des liposomes unilamellaires
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
JPS61271204A (ja) 1985-05-27 1986-12-01 Shiseido Co Ltd リポソ−ム製剤
IL79114A (en) 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
WO1987001938A1 (fr) 1985-09-27 1987-04-09 The Regents Of The University Of California Systeme d'administration transdermique de medicaments aux liposomes
JPS6295134A (ja) * 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
DE3542773A1 (de) 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
FR2597367B1 (fr) 1986-04-22 1988-07-15 Oreal Procede pour faciliter la formation de spherules lipidiques en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
DK86988A (da) 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
CA1323306C (fr) 1987-03-05 1993-10-19 Mircea C. Popescu Preparation comprenant une solution lipidique et un agent pharmacologique
US4855090A (en) 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US5238613A (en) 1987-05-20 1993-08-24 Anderson David M Microporous materials
IL86650A0 (en) 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
DE69013557D1 (de) 1989-04-21 1994-12-01 Otsuka Pharma Co Ltd An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
ATE104862T1 (de) * 1989-08-03 1994-05-15 Hisamitsu Pharmaceutical Co Hautcremezubereitung zur aeusserlichen verwendung.
AU6524990A (en) 1989-09-21 1991-04-18 Micro Vesicular Systems, Inc. Hybrid paucilamellar lipid vesicles
CA2067754C (fr) 1990-08-24 2002-06-04 Gregor Cevc Preparation visant l'application d'agents sous forme de mini- gouttelettes
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
JP2922017B2 (ja) 1991-03-25 1999-07-19 第一製薬株式会社 経口用脂質膜構造体
GEP19991583B (en) 1991-06-10 1999-04-29 Sanol Arznei Schwarz Gmbh Nitroglycerine Plaster and Method for Its Production
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
SE9200952D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
FR2714601B1 (fr) 1993-12-30 1996-02-09 Oreal Composition dépigmentante pour le traitement simultané des couches superficielles et profondes, son utilisation.
US5536263A (en) 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
IT1270678B (it) 1994-10-20 1997-05-07 Bayer Ag Liposomi al chetoprofen
US20020048596A1 (en) 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
DE19512181C2 (de) 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
WO1997021428A1 (fr) 1995-12-12 1997-06-19 Vesifact Ag Pulverisateur d'hydrocortisone pour administration topique
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
ATE493499T1 (de) 1996-08-09 2011-01-15 Keygene Nv Resistenz gegen schädlinge
CZ299790B6 (cs) 1996-08-22 2008-11-26 Skyepharma Canada Inc. Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic
WO1998030215A1 (fr) 1997-01-13 1998-07-16 Cilag Ag Formulation topique de tretinoine a base de liposomes
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
ES2284202T3 (es) 1997-05-14 2007-11-01 Senju Pharmaceutical Co., Ltd. Preparaciones acuosas en suspension con excelente redispersabilidad.
US5985379A (en) * 1997-07-22 1999-11-16 Franklin Mint Company Decorative display plate
ES2281981T3 (es) 1998-09-03 2007-10-01 Loma Linda University Medical Center Composicion farmaceutica y uso de aines para tratar la inflamacion.
EP1140021B1 (fr) * 1998-12-23 2004-08-04 Idea Ag Formulation amelioree pour l'application topique non invasive in vivo
DE69901284T2 (de) 1999-01-27 2002-11-28 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
AU2001277891A1 (en) 2000-07-26 2002-02-05 Alcon Universal Ltd. Pharmaceutical suspension compositions lacking a polymeric suspending agent
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition

Also Published As

Publication number Publication date
HRP20010309A2 (en) 2002-06-30
EP1140021A1 (fr) 2001-10-10
NO20013164D0 (no) 2001-06-22
EP1140021B1 (fr) 2004-08-04
KR100638150B1 (ko) 2006-10-26
HK1040629A1 (en) 2002-06-21
JP2002533379A (ja) 2002-10-08
CA2356080C (fr) 2009-05-12
DE69825495D1 (de) 2004-09-09
HUP0104424A2 (hu) 2002-03-28
CN1327382A (zh) 2001-12-19
ES2226203T3 (es) 2005-03-16
AU2513799A (en) 2000-07-31
RU2207844C2 (ru) 2003-07-10
WO2000038653A1 (fr) 2000-07-06
MXPA01006424A (es) 2002-06-04
CZ20012038A3 (cs) 2001-09-12
US20020064524A1 (en) 2002-05-30
CA2356080A1 (fr) 2000-07-06
PL193824B1 (pl) 2007-03-30
HK1040629B (zh) 2005-01-28
US7175850B2 (en) 2007-02-13
DE69825495T2 (de) 2005-07-28
PL349467A1 (en) 2002-07-29
CN1320880C (zh) 2007-06-13
TR200101790T2 (tr) 2001-10-22
AU770803B2 (en) 2004-03-04
ATE272391T1 (de) 2004-08-15
NO20013164L (no) 2001-08-22
KR20010107991A (ko) 2001-12-07
BR9816113A (pt) 2001-10-23
HRP20010309B1 (en) 2005-06-30
US20070184114A1 (en) 2007-08-09
HUP0104424A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
EE200100342A (xx) Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks
Marsh Controlling the oral biofilm with antimicrobials
Fine et al. In vivo antimicrobial effectiveness of an essential oil‐containing mouth rinse 12 h after a single use and 14 days' use
Ouhayoun Penetrating the plaque biofilm: impact of essential oil mouthwash
Greenstein Povidone‐iodine's effects and role in the management of periodontal diseases: a review
DE60134855D1 (de) Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen
DE60230021D1 (de) Systeme zur verabreichung eines kosmetischen und/oder therapeutischen wirkstoffes an mundoberflächen
NO971192D0 (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
FI955403A0 (fi) Valeltavia koostumuksia, jotka sisältävät polymeerimateriaalia, glykoleja ja glyseridejä
Gautam et al. In-vitro antimicrobial activity of different toothpastes
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
Mishra et al. Comparative evaluation of efficacy of 0.2% sodium hypochlorite (Hi Wash) mouthwash with 0.2% chlorhexidine mouthwash on plaque-induced gingivitis: A clinical trial
RS51154B (sr) Farmaceutske kompozicije koje sadrže niske koncentracije peroksida za lečenje i sprečavanje vaginalnih infekcija
FR2804865B1 (fr) Utilisation des corps gras particuliers permettant de modifier les proprietes physio-chimiques de la peau et/ou des muqueuses en tant qu'agents empechant ou diminuant l'adhesion des micro-organismes sur ces dernieres
Hamp et al. Some effects of chlorhexidine on the plaque flora of the beagle dog
Addy Local delivery of antimicrobial agents to the oral cavity
WO2001070184A3 (fr) Composition contenant des monoterpenes destinee a une administration orale topique
ME00858B (me) UPOTREBA 8a-AZALIDA U VETERINI KAO ANTIMIKROBNA SREDSTVA
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
CN106265165A (zh) 一种壳聚糖草本精油口腔清洁护理液及制备方法
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
AR032356A1 (es) Formulacion mejorada para aplicaciones topicas no invasivas in vivo
Lee Comparison of Antibacterial Activity of Ozonated Olive Oil and Chlorhexidine Gluconate
Ali et al. Anti-plaque and Anti-gingivitis Effect of Herbal Mouthwash